Skip to content
About
Company Overview
Management
Board of Directors
Scientific Advisory Board
Contact Us
Mission
Technology
Technology Overview
COVID-19
Annamycin
WP1066
WP1122
WP1732
WP1234
WP1220
Expanded Access
Pipeline
Partnerships
Partnering Inquiries
Science
News
Press Releases
Media Archive
Investors
Main Menu
Moleculin Biotech
A clinical-stage pharmaceutical company focused on the treatment of highly resistant cancers and viruses.
Acute Myeloid Leukemia
COVID-19
Skin Cancer
Pancreatic Cancer
Brain Tumors
Shareholder Letter 2020
Pancreatic Cancer
Acute Myeloid Leukemia
Brain Tumors
Skin Cancer
All SEC Filings
Investors
Overview
Overview
Presentations
Management Team
News / Events
Overview
Press Releases
IR Calendar
Email Alerts
FAQs
Financial Info
Overview
Balance Sheet
Income Statement
Cash Flow
Financial Results
Annual Report and Proxy
Stock Data
Quote
Charts
Historical Data
Analyst Coverage
SEC Filings
Overview
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Governance
Overview
Board of Directors
Board Committees
Governance Documents
Investor Tools
Email Alerts
Tear Sheet
Contacts
RSS News Feed
SEC Filings
Overview
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Filing Type:
View All
10-K
10-Q
10-Q/A
3
4
4/A
424B3
424B4
424B5
8-A12B
8-K
8-K/A
CERTNAS
CORRESP
CT ORDER
D
DEF 14A
DEFA14A
DRS
EFFECT
FWP
NT 10-K
NT 10-Q
POS AM
PRE 14A
PRER14A
RW
S-1
S-1/A
S-1MEF
S-3
S-3/A
S-3MEF
S-8
S-8 POS
SC 13G
SC 13G/A
UPLOAD
Year:
View All
2021
2020
2019
2018
2017
2016
2015
Date
Form
Description
PDF
XBRL
Pages
02/11/20
SC 13G
Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions
5
02/11/20
SC 13G
Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions
9
02/10/20
SC 13G/A
Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions
7
02/07/20
SC 13G
Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions
13
02/06/20
424B5
Prospectus filed pursuant to Rule 424(b)(5)
51
02/06/20
8-K
Current report filing
Documents
EX-1.1
EX-4.1
EX-4.2
EX-5.1
EX-10.1
92
02/06/20
424B5
Prospectus filed pursuant to Rule 424(b)(5)
1
02/05/20
8-K
Current report filing
Documents
EX-99.1
6
02/03/20
8-K
Current report filing
Documents
EX-99.1
8
01/21/20
RW
Registration Withdrawal Request
1
5
6
7
8
9
10
11
12
13
14
Go to Top